Wockhardt Limited has informed the Exchange regarding a press release dated April 01, 2025, titled Paediatric US Cancer Patient with Recalcitrant Blood and Liver Infection Successfully Treated with Zaynich (Zidebactam/Cefepime, WCK 5222)"
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wockhardt has shared a press release about a paediatric cancer patient in the US who was successfully treated for a severe, treatment-resistant blood and liver infection using its drug Zaynich (Zidebactam/Cefepime, also called WCK 5222). The case involved an infection that had not responded to other antibiotic options, making it a notable real-world clinical success. Zaynich is part of Wockhardt's antibiotic pipeline aimed at tackling drug-resistant (superbug) infections. The company appears to be using such case studies to build credibility and visibility for the product in international markets, particularly the US.
Positive news for Wockhardt's antibiotic franchise, as it showcases Zaynich's effectiveness in serious, hard-to-treat infections and may strengthen its positioning ahead of regulatory and commercial milestones. However, a single case study is unlikely to move the stock materially unless it signals broader clinical or commercial progress.